- Previous Close
0.9900 - Open
0.9798 - Bid 0.6860 x 100
- Ask 1.3000 x 200
- Day's Range
0.9798 - 1.0000 - 52 Week Range
0.7740 - 1.6900 - Volume
13,706 - Avg. Volume
138,436 - Market Cap (intraday)
35.565M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5800 - Earnings Date Apr 1, 2025 - Apr 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.88
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
renovorx.comRecent News: RNXT
View More
Performance Overview: RNXT
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNXT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNXT
View MoreValuation Measures
Market Cap
35.25M
Enterprise Value
25.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-93.31%
Return on Equity (ttm)
-258.95%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.16M
Diluted EPS (ttm)
-0.5800
Balance Sheet and Cash Flow
Total Cash (mrq)
9.56M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.19M